Literature DB >> 28419522

A general empirical model for renal drug handling in pharmacokinetic analyses.

Daniel F B Wright1, Stephen B Duffull1.   

Abstract

Dose adjustment in renal insufficiency is generally based on the assumption that renal drug clearance is related linearly to glomerular filtration rate. The theory underpinning this model is the intact nephron hypothesis, which says that impaired renal function is caused by a reduction in the number of complete (intact) nephrons. The purpose of the present commentary is to propose a general empirical model for renal drug handling. We will explore models for renal function under two scenarios: one that aligns with the intact nephron hypothesis, and one that relaxes the assumptions of this hypothesis. We propose that a nonlinear, non-intact nephron model will allow for differences in renal drug handling, while incorporating the intact nephron hypothesis model as a special case.
© 2017 The British Pharmacological Society.

Entities:  

Keywords:  NONMEM; creatinine clearance; intact nephron-hypothesis; pharmacokinetics; renal

Mesh:

Year:  2017        PMID: 28419522      PMCID: PMC5555866          DOI: 10.1111/bcp.13306

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  11 in total

1.  Influence of glomerular filtration rate on the rate of para-aminohippurate secretion by the rat kidney: micropuncture and clearance studies.

Authors:  D Häberle; A Ober; G Ruhland
Journal:  Kidney Int       Date:  1975-06       Impact factor: 10.612

2.  The pathologic physiology of chronic Bright's disease. An exposition of the "intact nephron hypothesis".

Authors:  N S BRICKER; P A MORRIN; S W KIME
Journal:  Am J Med       Date:  1960-01       Impact factor: 4.965

3.  Structural and functional adaptation in renal failure.

Authors:  R PLATT
Journal:  Br Med J       Date:  1952-06-28

4.  Structural and functional adaptation in renal failure.

Authors:  R PLATT
Journal:  Br Med J       Date:  1952-06-21

5.  GFR may not accurately predict aspects of proximal tubule drug handling.

Authors:  T L Putt; Stephen B Duffull; J B W Schollum; R J Walker
Journal:  Eur J Clin Pharmacol       Date:  2014-08-20       Impact factor: 2.953

6.  Dynamics of glomerular ultrafiltration in the rat. II. Plasma-flow dependence of GFR.

Authors:  B M Brenner; J L Troy; T M Daugharty; W M Deen; C R Robertson
Journal:  Am J Physiol       Date:  1972-11

7.  A study by micropuncture and microdissection of acute renal damage in rats.

Authors:  T U Biber; M Mylle; A D Baines; C W Gottschalk; J R Oliver; M C MacDowell
Journal:  Am J Med       Date:  1968-05       Impact factor: 4.965

8.  Variability in the renal clearance of cephalexin in experimental renal failure.

Authors:  A Maïza; P T Daley-Yates
Journal:  J Pharmacokinet Biopharm       Date:  1993-02

9.  Prediction of the renal clearance of cimetidine using endogenous N-1-methylnicotinamide.

Authors:  A Maiza; P T Daley-Yates
Journal:  J Pharmacokinet Biopharm       Date:  1991-04

10.  Differential effects of the degree of renal damage on p-aminohippuric acid and inulin clearances in rats.

Authors:  C A Gloff; L Z Benet
Journal:  J Pharmacokinet Biopharm       Date:  1989-04
View more
  3 in total

1.  A population pharmacokinetic model of intravenous telavancin in healthy individuals to assess tissue exposure.

Authors:  Sami Ullah; Peter Matzneller; Markus Zeitlinger; Uwe Fuhr; Max Taubert
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2019-05-06       Impact factor: 3.000

2.  Population pharmacokinetics of lenalidomide in patients with B-cell malignancies.

Authors:  Jim H Hughes; Mitch A Phelps; Richard N Upton; Stephanie E Reuter; Yue Gao; John C Byrd; Michael R Grever; Craig C Hofmeister; Guido Marcucci; William Blum; Kristie A Blum; David J R Foster
Journal:  Br J Clin Pharmacol       Date:  2019-02-27       Impact factor: 4.335

3.  A general empirical model for renal drug handling in pharmacokinetic analyses.

Authors:  Daniel F B Wright; Stephen B Duffull
Journal:  Br J Clin Pharmacol       Date:  2017-05-10       Impact factor: 4.335

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.